Header Logo

Connection

MICHAEL ITTMANN to Biomarkers, Tumor

Back to Details
This is a "connection" page, showing publications MICHAEL ITTMANN has written about Biomarkers, Tumor.
MICHAEL ITTMANN
Connection Strength
1.648
Biomarkers, Tumor
  1. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase. Prostate. 2006 Jun 01; 66(8):847-57.
    View in: PubMed
    Score: 0.135
  2. Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer. Cell Rep Med. 2025 Aug 19; 6(8):102255.
    View in: PubMed
    Score: 0.127
  3. CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation. Neoplasia. 2021 11; 23(11):1147-1165.
    View in: PubMed
    Score: 0.098
  4. CASC11 promotes aggressiveness of prostate cancer cells through miR-145/IGF1R axis. Prostate Cancer Prostatic Dis. 2021 09; 24(3):891-902.
    View in: PubMed
    Score: 0.094
  5. Kallikrein gene family as biomarkers for recurrent prostate cancer. Croat Med J. 2020 Oct 31; 61(5):450-456.
    View in: PubMed
    Score: 0.091
  6. Association of Genetic Ancestry With DNA Methylation Changes in Prostate Cancer Disparity. Anticancer Res. 2019 Nov; 39(11):5861-5866.
    View in: PubMed
    Score: 0.085
  7. Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases. Clin Cancer Res. 2018 05 01; 24(9):2182-2193.
    View in: PubMed
    Score: 0.076
  8. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 2017 10; 72(4):641-649.
    View in: PubMed
    Score: 0.072
  9. Cellular interactions of the phosphorylated form of AKT in prostate cancer. Hum Pathol. 2017 05; 63:98-109.
    View in: PubMed
    Score: 0.071
  10. Positive association of collagen type I with non-muscle invasive bladder cancer progression. Oncotarget. 2016 Dec 13; 7(50):82609-82619.
    View in: PubMed
    Score: 0.070
  11. Identification of microRNA profile specific to cancer stem-like cells directly isolated from human larynx cancer specimens. BMC Cancer. 2016 11 05; 16(1):853.
    View in: PubMed
    Score: 0.069
  12. The Germ Cell Gene TDRD1 as an ERG Target Gene and a Novel Prostate Cancer Biomarker. Prostate. 2016 10; 76(14):1271-84.
    View in: PubMed
    Score: 0.067
  13. Expression of ERG protein in prostate cancer: variability and biological correlates. Endocr Relat Cancer. 2015 Jun; 22(3):277-87.
    View in: PubMed
    Score: 0.063
  14. Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer. Prostate. 2014 Nov; 74(15):1498-505.
    View in: PubMed
    Score: 0.060
  15. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer. Int J Cancer. 2015 Feb 15; 136(4):875-9.
    View in: PubMed
    Score: 0.059
  16. miR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer. PLoS One. 2014; 9(6):e98675.
    View in: PubMed
    Score: 0.059
  17. MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas. J Neurooncol. 2013 Nov; 115(2):143-51.
    View in: PubMed
    Score: 0.055
  18. Biological correlates of biochemical recurrence free survival using multiple markers in a large tissue microarray cohort. Ann Clin Lab Sci. 2013; 43(1):11-21.
    View in: PubMed
    Score: 0.053
  19. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One. 2008 Apr 30; 3(4):e2079.
    View in: PubMed
    Score: 0.038
  20. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol. 2007 May; 177(5):1753-8.
    View in: PubMed
    Score: 0.036
  21. CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther. 2006 Jan; 5(1):78-83.
    View in: PubMed
    Score: 0.033
  22. Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis. Hum Pathol. 2022 04; 122:84-91.
    View in: PubMed
    Score: 0.025
  23. Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clin Cancer Res. 2000 Sep; 6(9):3430-3.
    View in: PubMed
    Score: 0.023
  24. MicroRNAs as prognostic markers in prostate cancer. Prostate. 2019 02; 79(3):265-271.
    View in: PubMed
    Score: 0.020
  25. Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6101-11.
    View in: PubMed
    Score: 0.014
  26. A dosage-dependent pleiotropic role of Dicer in prostate cancer growth and metastasis. Oncogene. 2014 Jun 12; 33(24):3099-108.
    View in: PubMed
    Score: 0.014
  27. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol. 2010 Jul; 184(1):149-56.
    View in: PubMed
    Score: 0.011
  28. PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer. Int J Cancer. 2006 Mar 15; 118(6):1471-80.
    View in: PubMed
    Score: 0.008
  29. Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers. Int J Cancer. 2005 Feb 20; 113(5):811-8.
    View in: PubMed
    Score: 0.008
  30. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 2005; 8(2):108-18.
    View in: PubMed
    Score: 0.008
  31. The role of caveolin-1 in androgen insensitive prostate cancer. J Urol. 2002 Oct; 168(4 Pt 1):1589-96.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.